28 June 2023

TruSpine Technologies plc
("**TruSpine**" or the "**Company**")

Loan repayment & Update

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that, further to the announcement on 25 April 2023, the Company has repaid the £100,000 loan and accrued interest under the Loan Agreement with Annabel Schild. The Funding Loan was repaid from existing cash resources following receipt of a HMRC R&D tax credit of approximately £200,000 ("Tax Credit").

Update on Working Capital

The Company has limited working capital resources and continues to carefully manage its cash position.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company's announcement of 25 April 2023.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

TruSpine Technologies Plc	Tel: +44 (0)20 7118 0852
Laurence Strauss, Chief Executive Officer	
Cairn Financial Advisers LLP (AQSE Corporate Adviser)	Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti	
Oberon Capital (Joint Broker)	Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford	
Peterhouse Capital Limited (Joint Broker & Financial Adviser)	Tel: +44 (0)20 7469 0930
Lucy Williams / Duncan Vasey	
Novus Communications (PR and IR)	Tel: +44 (0)20 7448 9839
Alan Green / Jacqueline Briscoe	novuscomms@truspine.org